Now Approved in the U.S.
Building on Our Impossible Firsts, We Can Change the Course of Human Health
Ionis is unlocking the rapidly expanding potential of RNA- and DNA-targeted medicines to enable better futures for people living with serious diseases.
Rick
Living with FCS
Our Science and Technology
Rooted in a Deep Understanding of Genetics
The genetic basis of human disease continues to inspire our science and technology as we expand to new therapeutic approaches, while our industry-leading chemistry helps us target the right medicine to the right disease – providing a rich source for future breakthroughs and transformative impact.
WHO WE ARE
Ionis unites groundbreaking science and technology with relentless passion to discover and deliver medicines that enable better futures for people living with serious diseases.
Our commitment to changing lives is a calling that pushes us to deliver the next solution for patients and those who care for them.
We have set our sights on providing new solutions across the spectrum of diseases, from common intractable neurologic conditions to cardiometabolic disorders and select areas of high patient needs.
We push beyond the impossible to unleash the potential of patients – and those who care for them – enabling them to make their own impact on the world.
We believe operating responsibly and sustainably creates long-term value and a positive impact for our company, stakeholders, patients, communities and the broader world.
JOIN OUR TEAM
Seizing the Moment to Unlock the Potential of RNA- and DNA-Targeted Medicines
If you’re driven to deliver on the promise of groundbreaking medicines that empower patients and caregivers to make their own impact on the world, come join us.
LATEST NEWS FEED
Sign Up for News Alerts
For the latest on Ionis news and developments
CARLSBAD, Calif. --(BUSINESS WIRE)--Jun. 12, 2025-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Richard Geary , Ph.D., executive vice president and chief development officer, will retire effective January 2026 and that Holly Kordasiewicz , Ph.D., currently senior vice president,
- Completion of enrollment anticipated in 2026 - CARLSBAD, Calif. --(BUSINESS WIRE)--Jun. 11, 2025-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the first participant has been dosed in the global Phase 3 REVEAL study, which is designed to evaluate the efficacy and safety of
– Olezarsen met the primary endpoint with a statistically significant mean reduction in triglycerides versus placebo at 80 mg and 50 mg doses – – Olezarsen met all key secondary endpoints – – Olezarsen demonstrated a favorable safety and tolerability profile – – Nearly 1,500-person Phase 3 study
Click here to read an important notice about a cybersecurity incident relating to services provided to WEX Health (an Ionis employee benefits plan administrator).